Enoxaparin as Treatment for Vulvodynia

Enoxaparin as Treatment for Vulvar Vestibulitis Syndrome - Vulvodynia

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00874484

Enrollment

Registered

2009-04-02

Start date

2009-03-31

Completion date

2011-05-31

Last updated

2020-05-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vulvodynia

Brief summary

The investigators hypothesize that injections of Low molecular weight heparin (LMWH) \[enoxaparin\] will reduce pain in women with vulvodynia.

Interventions

DRUGClexane (enoxaparin)

One arm receives enoxoparin, second arm receives saline

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

FEMALE

Age

19 Years to 50 Years

Healthy volunteers

Yes

Inclusion criteria

* women with vulvodynia

Exclusion criteria

* women without vulvodynia

Design outcomes

Primary

Measure	Time frame
vestibular pain	one year

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026